

Human Respiratory Syncytial Virus A, A2023/06-12NSMM

Catalog No. NR-59660

Product Description:

Human respiratory syncytial virus A (hRSV A), A2023/06-12NSMM was isolated from a nasopharyngeal swab from a pediatric patient June 12, 2023, in Atlanta, Georgia, USA. NR-59660 lot 70065879 was produced by infecting human epithelial carcinoma cells (HEp-2; ATCC® CCL-23™) with the deposited material and incubating in Eagle’s Minimum Essential Medium (ATCC® 30-2003™) supplemented with 2% fetal bovine serum (ATCC® 30-2020™) for 4 days at 37°C with 5% CO₂.

Passage History:

HEp-2(1)/HEp-2(1) (Emory University School of Medicine/BEI Resources); HEp-2 = human epithelial carcinoma cells

Lot: 70065879

Manufacturing Date: 16APR2024

TEST	SPECIFICATIONS	RESULTS
Identification by Infectivity in HEp-2 Cells	Cell rounding and syncytia formation	Cell rounding and syncytia formation
Next-Generation Sequencing (NGS) of Complete Genome Using Illumina® MiSeq™ Platform	≥ 98% identity with hRSV A	99.8% identity with hRSV A ¹
Titer by TCID₅₀ Assay in HEp-2 Cells by Immunofluorescent Assay^{2,3} (7 days at 37°C with 5% CO ₂)	Report results	2.8 × 10 ⁶ TCID ₅₀ /mL
Sterility (21-day incubation) Harpo’s HTYE broth, 37°C and 26°C, aerobic ⁴ Trypticase Soy broth, 37°C and 26°C, aerobic Sabouraud broth, 37°C and 26°C, aerobic Sheep blood agar, 37°C, aerobic Sheep blood agar, 37°C, anaerobic Thioglycollate broth, 37°C, anaerobic DMEM with 10% FBS, 37°C, aerobic	No growth No growth No growth No growth No growth No growth No growth	No growth No growth No growth No growth No growth No growth No growth
Mycoplasma Contamination Agar and broth culture (14-day incubation at 37°C) DNA detection by PCR of extracted Test Article nucleic acid	None detected None detected	None detected None detected

¹The genome of hRSV A, A2023/06-12NSMM has been sequenced (OR987486.1) recently. The sequence was compared with reference hRSV A, ASU102744 (GenBank: OR143200.1) that was available at the time and showed 99.8% identity to this reference OR143200.1.

²The Tissue Culture Infectious Dose 50% (TCID₅₀) endpoint is the 50% infectious endpoint in cell culture. The TCID₅₀ is the dilution of virus that under the conditions of the assay can be expected to infect 50% of the culture vessels inoculated, just as a Lethal Dose 50% (LD₅₀) is expected to kill half of the animals exposed. A reciprocal of the dilution required to yield the TCID₅₀ provides a measure of the titer (or infectivity) of a virus preparation.

³Test performed with goat anti-RSV primary antibody (BioRad 7950-0004) and rabbit anti-goat IgG(Fc):FITC secondary antibody (BioRad STAR122F)

⁴Atlas, Ronald M. *Handbook of Microbiological Media*. 3rd ed. Ed. Lawrence C. Parks. Boca Raton: CRC Press, 2004, p. 798.

/Sonia Bjorum Brower/
Sonia Bjorum Brower

25 JUN 2025

Technical Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®’s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

